Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with alpelisib for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
- Associated Therapies
- -
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
- Conditions
- Interventions
- First Posted Date
- 2017-02-17
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 379
- Registration Number
- NCT03056755
- Locations
- 🇺🇸
Kaiser Permanente Medical Group, Anaheim, California, United States
🇺🇸UCSF, San Francisco, California, United States
🇺🇸University of Louisville James Graham Brown Cancer Center, Louisville, Kentucky, United States
Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-01-02
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 55
- Registration Number
- NCT03007979
- Locations
- 🇺🇸
University of Nebraska, Lincoln, Nebraska, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT03006172
- Locations
- 🇺🇸
Massachusetts General Hospital., Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 14
- Registration Number
- NCT02983604
- Locations
- 🇺🇸
Stanford Women's Cancer Center, Stanford, California, United States
🇺🇸Allina Health, Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States
🇺🇸Medical Oncology Associates, PS (dba Summit Cancer Centers), Spokane, Washington, United States
G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT02983071
- Locations
- 🇧🇬
Special Hospital For Active Treatment In Oncology, Sofia, Bulgaria
🇧🇬MHAT for Womens Health - Nadezhda OOD, Sofia, Bulgaria
🇲🇩The Institute of Oncology, Chisinau, Moldova, Republic of
SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2019-07-12
- Lead Sponsor
- Evgen Pharma
- Target Recruit Count
- 60
- Registration Number
- NCT02970682
- Locations
- 🇧🇪
Grand Hopital de Charleroi, Service D'Oncologie-Hematologie, Charleroi, Belgium
🇧🇪Saint-Luc hospital, Brussels, Woluwe-Saint-Lambert, Belgium
🇫🇷ICO René Gauducheau, St Herblain, Nantes, Loire Atlantique, France
Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer
- First Posted Date
- 2016-11-16
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 124
- Registration Number
- NCT02964507
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-11-08
- Last Posted Date
- 2020-09-02
- Lead Sponsor
- Lund University Hospital
- Target Recruit Count
- 126
- Registration Number
- NCT02958852
- Locations
- 🇸🇪
Lund University Hospital, Department of Oncology, Lund, Sweden
Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 61
- Registration Number
- NCT02955394
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸West Cancer Center, Germantown, Tennessee, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-10-28
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 496
- Registration Number
- NCT02947685
- Locations
- 🇺🇸
University of Maryland - Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸The University of Chicago Medical Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.